PetMed Express Faces Investigation Over Earnings Delays, Stock Plummets 32.41%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: PRnewswire
- Earnings Delay Impact: On June 10, 2025, PetMed announced a delay in releasing its Q4 and FY2025 earnings, causing its stock to drop 11.22% to $3.72 per share the following day, indicating investor concerns over financial transparency.
- Internal Investigation Effects: On July 1, 2025, PetMed delayed its annual report due to an internal investigation into revenue recognition, resulting in a 1.51% stock decline to $3.27 per share, reflecting a decrease in market confidence regarding corporate governance.
- Quarterly Report Delay: On November 12, 2025, PetMed disclosed it could not timely file its Q3 report, leading to a significant 32.41% drop in stock price to $1.96 per share, highlighting ongoing compliance and audit challenges.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether PetMed and its executives engaged in securities fraud, which could further impact the company's reputation and shareholder confidence, increasing legal risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PETS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PETS
About PETS
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PetMed Express Faces Investigation Over Delayed Earnings, Stock Plummets 32.41%
- Financial Audit Delay: PetMed Express announced on June 10, 2025, a delay in releasing its Q4 and fiscal year 2025 earnings, causing a stock drop of 11.22% the following day, reflecting investor concerns over the company's financial transparency.
- Impact of Internal Investigation: On July 1, 2025, PetMed delayed its annual report due to an internal investigation into revenue recognition, leading to a 1.51% decline in stock price, indicating that governance and compliance issues may undermine investor confidence.
- Quarterly Report Delay: On November 12, 2025, PetMed disclosed it could not timely file its Q3 report, resulting in a 32.41% plunge in stock price to $1.96, highlighting a significant crisis in financial management that could lead to broader legal and financial repercussions.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether PetMed engaged in securities fraud or other unlawful business practices, suggesting the company faces potential legal liabilities that could further impact its market performance and shareholder interests.
Continue Reading
PetMed Express Faces Investigation Over Delayed Earnings, Stock Plummets 32.41%
- Audit Delay: On June 10, 2025, PetMed Express announced a delay in releasing its Q4 and fiscal year 2025 earnings, causing its stock to drop 11.22% the following day, reflecting market concerns over the company's financial transparency.
- Internal Investigation Impact: On July 1, 2025, PetMed delayed its annual report due to an internal investigation into revenue recognition, leading to a 1.51% decline in stock price, indicating a weakening investor confidence in corporate governance.
- Quarterly Report Delay: On November 12, 2025, PetMed disclosed it could not timely file its Q3 report, resulting in a 32.41% stock plunge to $1.96, highlighting severe financial compliance issues that may affect future financing capabilities.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether PetMed engaged in securities fraud or other unlawful business practices, which could lead to further legal liabilities and financial losses, increasing uncertainty for investors.
Continue Reading